Thirona spins out retina business to pursue long-term growth plans

Article

To advance the company’s ability to anticipate on increasing patients’ needs and to pursue long-term growth plans in both fields of expertise, the company decided to spin out its retina division.

Thirona specializes in artificial intelligence for lung and retinal image analysis allowing for precise quantification of abnormalities related to pulmonary and eye diseases.

Thirona specializes in artificial intelligence for lung and retinal image analysis allowing for precise quantification of abnormalities related to pulmonary and eye diseases.

Thirona this week announced plans to spin out its retina division into Thirona Retina BV, effective Jan. 1.

According to a news release, Thirona specializes in artificial intelligence for lung and retinal image analysis allowing for precise quantification of abnormalities related to pulmonary and eye diseases. The company noted that the high-precision analyses contribute to development of innovative solutions for screening, diagnostics, and personalized patient treatment.

To advance the company’s ability to anticipate on increasing patients’ needs and to pursue long-term growth plans in both fields of expertise, the company decided to spin out its retina division.

While building further on the scientific heritage and technology expertise of Thirona in the field of AI-assisted medical image analysis, Thirona Retina BV will focus entirely on the eye diseases market and act as a stand-alone legal entity. Thirona BV will continue to concentrate on AI-powered solutions for precision medicine in lung diseases, in partnership with pharmaceutical, med-tech and clinical care integration companies.

“To ensure business continuity and to allow our new entity to grow in a focused manner, Thirona BV will continue to support the Retina team with shared resources, where needed,” Eva van Rikxoort, founder and CEO of Thirona, said in the news release. “We are happy to see our retina business maturing and quickly gaining market traction.”

Mark van Grinsven, managing director of Thirona Retina BV, pointed out that the company is convinced that the move will help the company’s retina team to fully concentrate on the development of AI-powered solutions for eye diseases, to support growing patients’ needs and to intensify partnerships with our channel partners in eye care markets.

“The Class IIa European MDR CE certified RetCAD is already being integrated by all major fundus camera providers such as iCare, Topcon, Canon, Tomey and Nidek,” he said. “More dedication will allow us to speed up the expansion to other channels and to grow our leadership position globally.”

“This formal separation ensures that both companies are optimally positioned to pursue their growth plans and maximizes the ability to create value in their respective markets,” says Guido Geerts, Partner and co-CEO of Thirona BV.

Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.